CancerData
Not a member yet
37 research outputs found
Sort by
Data from: MMP2 small immuno protein antibody uptake in xenograft tumors is associated with MMP2 activity
No full textThis dataset supports the publication by Kranthi Panth, et al. In this study, it is hypothesized that aMMP2-SIP, a small immuno protein antibody targeting the catalytic domain of human MMP2 distinctively detects MMP2 in the tumors. MMP2 plays a vital role in tumorigenesis, angiogenesis and tumor invasion
PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes.
Full text linkBACKGROUND AND PURPOSE: We compared two imaging biomarkers for dose-escalation in patients with advanced non-small cell lung cancer (NSCLC). Treatment plans boosting metabolically active sub-volumes defined by FDG-PET or hypoxic sub-volumes defined by HX4-PET were compared with boosting the entire tumour.MATERIALS AND METHODS: Ten NSCLC patients underwent FDG- and HX4-PET/CT scans prior to radiotherapy. Three isotoxic dose-escalation plans were compared per patient: plan A, boosting the primary tumour (PTVprim); plan B, boosting sub-volume with FDG >50% SUVmax (PTVFDG); plan C, boosting..
A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients.
No full textPURPOSE: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the TNM staging system, they form a heterogeneous group, which is reflected in the survival outcome. The increasing amount of information for an individual patient and the growing number of treatment options facilitate personalized treatment, but they also complicate treatment decision making. Decision support systems (DSS), which provide individualized prognostic information, can overcome this but are currently lacking. A DSS for stage III NSCLC requires the development and integration..
Data from: Development and Evaluation of an Online Three-Level Proton vs Photon Decision Support Prototype for Head and Neck Cancer - Comparison of Dose, Toxicity and Cost-Effectiveness
No full textThis dataset supports the publication by Cheng et al, entitled "Development and Evaluation of an Online Three-Level Proton vs Photon Decision Support Prototype for Head and Neck Cancer - Comparison of Dose, Toxicity and Cost-Effectiveness". It was used to evaluate the PRODECIS decision support prototype for online evaluation of eligiblilty for proton therapy using Dutch guidelines.
The Head and Neck test dataset was based on the ROCOCO dataset by HP van der Laan, as described in doi:10.3109/0284186X.2012.692885
Data from: A validated Tumor Control Probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy
No full textThis dataset supports the publication by Walsh et al, entitled "A validated Tumor Control Probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy"
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.
No full textHuman cancers exhibit strong phenotypic differences that can be visualized noninvasively by medical imaging. Radiomics refers to the comprehensive quantification of tumour phenotypes by applying a large number of quantitative image features. Here we present a radiomic analysis of 440 features quantifying tumour image intensity, shape and texture, which are extracted from computed tomography data of 1,019 patients with lung or head-and-neck cancer. We find that a large number of radiomic features have prognostic power in independent data sets of lung and head-and-neck cancer patients, many of..
International data-sharing for radiotherapy research: an open-source based infrastructure for multicentric clinical data mining.
No full textExtensive, multifactorial data sharing is a crucial prerequisite for current and future (radiotherapy) research. However, the cost, time and effort to achieve this are often a roadblock. We present an open-source based data-sharing infrastructure between two radiotherapy departments, allowing seamless exchange of de-identified, automatically translated clinical and biomedical treatment data
Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging.
No full textPURPOSE: Due to the established role of the human papillomavirus (HPV), the optimal treatment for oropharyngeal carcinoma is currently under debate. We evaluated the most important determinants of treatment outcome to develop a multifactorial predictive model that could provide individualized predictions of treatment outcome in oropharyngeal carcinoma patients.METHODS: We analyzed the association between clinico-pathological factors and overall and progression-free survival in 168 OPSCC patients treated with curative radiotherapy or concurrent chemo-radiation. A multivariate model was..
